Your request to link to rcsb for JNK1/JNK2

• 1JNK: the c-jun n-terminal kinase (jnk3s) complexed with mgamp-pnp (10.1016/S0969-2126(98)00100-2 )
• 1PMN: crystal structure of jnk3 in complex with an imidazole-pyrimidine inhibitor (10.1016/S1074-5521(03)00159-5 )
• 1PMU: the crystal structure of jnk3 in complex with a phenantroline inhibitor (10.1016/S1074-5521(03)00159-5 )
• 1PMV: the structure of jnk3 in complex with a dihydroanthrapyrazole inhibitor (10.1016/S1074-5521(03)00159-5 )
• 1UKH: structural basis for the selective inhibition of jnk1 by the scaffolding protein jip1 and sp600125 (10.1038/SJ.EMBOJ.7600212 )
• 1UKI: structural basis for the selective inhibition of jnk1 by the scaffolding protein jip1 and sp600125 (10.1038/SJ.EMBOJ.7600212 )
• 2B1P: inhibitor complex of jnk3 (10.1016/J.BMCL.2005.06.083 )
• 2EXC: inhibitor complex of jnk3
• 2G01: pyrazoloquinolones as novel, selective jnk1 inhibitors (10.1016/J.BMCL.2006.02.046 )
• 2GMX: selective aminopyridine-based c-jun n-terminal kinase inhibitors with cellular activity (10.1021/JM060199B )
• 2H96: discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-jun nh2-terminal kinase inhibitors (10.1021/JM060465L )
• 2NO3: novel 4-anilinopyrimidines as potent jnk1 inhibitors (10.1016/J.BMCL.2006.10.093 )
• 2O0U: crystal structure of human jnk3 complexed with n-{3-cyano-6-[3-(1- piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}- 1-naphthalenecarboxamide (10.1016/J.BMCL.2006.12.003 )
• 2O2U: crystal structure of human jnk3 complexed with n-(3-cyano-4,5,6,7- tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide (10.1016/J.BMCL.2006.12.003 )
• 2OK1: crystal structure of jnk3 bound to n-benzyl-4-(4-(3-chlorophenyl)-1h- pyrazol-3-yl)-1h-pyrrole-2-carboxamide (10.1021/JM061381F )
• 2P33: synthesis and sar of aminopyrimidines as novel c-jun n-terminal kinase (jnk) inhibitors (10.1016/J.BMCL.2007.03.078 )
• 2R9S: c-jun n-terminal kinase 3 with 3,5-disubstituted quinoline inhibitor (10.1016/J.BMCL.2007.08.054 )
• 2WAJ: crystal structure of human jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitor (10.1016/J.BMCL.2009.02.098 )
• 2XRW: linear binding motifs for jnk and for calcineurin antagonistically control the nuclear shuttling of nfat4 (10.1126/SCISIGNAL.2003004 )
• 2ZDT: crystal structure of human jnk3 complexed with an isoquinolone inhibitor (10.1016/J.BMC.2008.02.028 )
• 2ZDU: crystal structure of human jnk3 complexed with an isoquinolone inhibitor (10.1016/J.BMC.2008.02.027 )
• 3CGF: irak-4 inhibitors (part ii)- a structure based assessment of imidazo[1,2 a]pyridine binding (10.1016/J.BMCL.2008.04.039 )
• 3CGO: irak-4 inhibitors (part ii)- a structure based assessment of imidazo[1,2 a]pyridine binding (10.1016/J.BMCL.2008.04.039 )
• 3DA6: crystal structure of human jnk3 complexed with n-(3-methyl-4-(3-(2- (methylamino)pyrimidin-4-yl)pyridin-2-yloxy)naphthalen-1-yl)-1h- benzo[d]imidazol-2-amine (10.1016/J.BMCL.2008.11.056 )
• 3E7O: crystal structure of jnk2 (10.1016/J.JMB.2008.08.086 )
• 3ELJ: jnk1 complexed with a bis-anilino-pyrrolopyrimidine inhibitor. (10.1016/J.BMCL.2008.11.077 )
• 3FI3: crystal structure of jnk3 with indazole inhibitor, sr-3737 (10.1074/JBC.M809430200 )
• 3FV8: jnk3 bound to piperazine amide inhibitor, sr2774. (10.1016/J.BMCL.2009.03.086 )
• 3G90: jnk-3 bound to (z)-5-fluoro-1-((6-fluoro-4h-benzo[d][1,3]dioxin-8-yl) methyl)-3-(hydroxyimino)indolin-2-one (10.1016/J.BMCL.2009.03.043 )
• 3G9L: jnk3 bound to (z)-1-((6-fluoro-4h-benzo[d][1,3]dioxin-8-yl)methyl)-3- (hydroxyimino)-4-styrylindolin-2-one (10.1016/J.BMCL.2009.03.043 )
• 3G9N: jnk3 bound to (z)-1-((6-fluoro-4h-benzo[d][1,3]dioxin-8-yl)methyl)-3- (hydroxyimino)-4-phenylindolin-2-one (10.1016/J.BMCL.2009.03.043 )
• 3KVX: jnk3 bound to aminopyrimidine inhibitor, sr-3562 (10.1021/JM901351F )
• 3NPC: crystal structure of jnk2 complexed with birb796 (10.1016/J.BMCL.2010.06.157 )
• 3O17: crystal structure of jnk1-alpha1 isoform
• 3O2M: crystal structure of jnk1-alpha1 isoform complex with a biaryl tetrazol (a-82118) (10.1021/CB1002619 )
• 3OXI: design and synthesis of disubstituted thiophene and thiazole based inhibitors of jnk for the treatment of neurodegenerative diseases (10.1016/J.BMCL.2010.10.066 )
• 3OY1: highly selective c-jun n-terminal kinase (jnk) 2 and 3 inhibitors with in vitro cns-like pharmacokinetic properties (10.1016/J.BMCL.2010.11.010 )
• 3PTG: design and synthesis of a novel, orally efficacious tri-substituted thiophene based jnk inhibitor (10.1016/J.BMCL.2011.01.046 )
• 3PZE: jnk1 in complex with inhibitor (10.1021/JM300025R )
• 3RTP: design and synthesis of brain penetrant selective jnk inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration (10.1016/J.BMCL.2011.06.100 )
• 3TTI: crystal structure of jnk3 complexed with cc-930, an orally active anti-fibrotic jnk inhibitor (10.1016/J.BMCL.2011.12.027 )
• 3TTJ: crystal structure of jnk3 complexed with cc-359, a jnk inhibitor for the prevention of ischemia-reperfusion injury (10.1016/J.BMCL.2011.12.028 )
• 3V6R: discovery of potent and selective covalent inhibitors of jnk (10.1016/J.CHEMBIOL.2011.11.010 )
• 3V6S: discovery of potent and selective covalent inhibitors of jnk (10.1016/J.CHEMBIOL.2011.11.010 )
• 3VUD: crystal structure of a cysteine-deficient mutant m1 in map kinase jnk1 (10.1021/BI300918W )
• 3VUG: crystal structure of a cysteine-deficient mutant m2 in map kinase jnk1 (10.1021/BI300918W )
• 3VUH: crystal structure of a cysteine-deficient mutant m3 in map kinase jnk1 (10.1021/BI300918W )
• 3VUI: crystal structure of a cysteine-deficient mutant m2 in map kinase jnk1 (10.1021/BI300918W )
• 4AWI: human jnk1alpha kinase with 4-phenyl-7-azaindole ikk2 inhibitor. (10.1016/J.BMCL.2012.06.065 )
• 4E73: crystal structure of jnk1beta-jip in complex with an azaquinolone inhbitor (10.1021/ML300175C )
• 4G1W: crystal structure of jnk1 in complex with jip1 peptide and 7-fluoro-3- [4-(2-hydroxy-ethanesulfonyl)-benzyl]-4-oxo-1-phenyl-1,4-dihydro- quinoline-2-carboxylic acid methyl ester
• 4H36: crystal structure of jnk3 in complex with atf2 peptide (10.1016/J.STR.2012.09.021 )
• 4H39: crystal structure of jnk3 in complex with jip1 peptide (10.1016/J.STR.2012.09.021 )
• 4H3B: crystal structure of jnk3 in complex with sab peptide (10.1016/J.STR.2012.09.021 )
• 4HYS: crystal structure of jnk1 in complex with jip1 peptide and 4-(4- indazol-1-yl-pyrimidin-2-ylamino)-cyclohexan (10.1016/J.BMCL.2012.12.047 )
• 4HYU: crystal structure of jnk1 in complex with jip1 peptide and 4-{4-[4-(3- methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}- cyclohexan (10.1016/J.BMCL.2012.12.047 )
• 4IZY: crystal structure of jnk1 in complex with jip1 peptide and 4-{4-[4-(4- methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}- cyclohexan (10.1016/J.BMCL.2013.04.029 )
• 4KKE: the crystal structure of amp-bound jnk3
• 4KKG: crystal structure of apo and amp-bound jnk3
• 4KKH: the crystal structure of inhibitor-bound jnk3
• 4L7F: co-crystal structure of jnk1 and ax13587 (10.1016/J.BMCL.2013.06.087 )
• 4QTD: structure of human jnk1 in complex with sch772984 and the amppnp- hydrolysed triphosphate revealing the second type-i binding mode (10.1038/NCHEMBIO.1629 )
• 4U79: crystal structure of human jnk3 in complex with a benzenesulfonamide inhibitor. (10.1021/ML500315B )
• 4UX9: crystal structure of jnk1 bound to a mkk7 docking motif (10.1073/PNAS.1419528112 )
• 4W4V: jnk2/3 in complex with 3-(4-{[(2-chlorophenyl)carbamoyl]amino}-1h- pyrazol-1-yl)-n-(2-methylpyridin-4-yl)benzamide (10.1038/SREP08047 )
• 4W4W: jnk2/3 in complex with n-(2-methylpyridin-4-yl)-3-{4- [(phenylcarbamoyl)amino]-1h-pyrazol-1-yl}benzamide (10.1038/SREP08047 )
• 4W4X: jnk2/3 in complex with 3-(4-{[(4-fluorophenyl)carbamoyl]amino}-1h- pyrazol-1-yl)-n-(2-methylpyridin-4-yl)benzamide (10.1038/SREP08047 )
• 4W4Y: jnk2/3 in complex with 3-(4-{[(4-methylphenyl)carbamoyl]amino}-1h- pyrazol-1-yl)-n-(2-methylpyridin-4-yl)benzamide (10.1038/SREP08047 )
• 4WHZ: design and synthesis of highly potent and isoform selective jnk3 inhibitors: sar studies on aminopyrazole derivatives (10.1021/JM501256Y )
• 4X21: the map kinase jnk3 as target for halogen bonding (10.1021/JACS.5B07090 )
• 4Y46: pyridopyrimidinone derivatives as potent and selective c-jun n- terminal kinase (jnk) inhibitors (10.1021/ML500474D )
• 4Y5H: pyridopyrimidinone derivatives as potent and selective c-jun n- terminal kinase (jnk) inhibitors (10.1021/ML500474D )
• 4YR8: crystal structure of jnk in complex with a regulator protein (10.1038/NCOMMS10879 )
• 4Z9L: the structure of jnk3 in complex with an imidazole-pyrimidine inhibitor
• 5LW1: crystal structure of darpin-darpin rigid fusion, variant dd_232_11_d12 in complex jnk1a1 and jip1 peptide (10.1016/J.JMB.2017.10.032 )
• 6EKD: crystal structure of jnk3 in complex with a pyridinylimidazole inhibitor (10.1021/ACSOMEGA.8B00668 )
• 6EMH: crystal structure of jnk3 in complex with a pyridinylimidazole inhibitor (10.1021/ACSOMEGA.8B00668 )
• 6EQ9: crystal structure of jnk3 in complex with amp-pcp (10.1021/ACSOMEGA.8B00668 )
• 6F5E: crystal structure of darpin-darpin rigid fusion, variant dd_d12_10_47 in complex jnk1a1 and jip1 peptide
• 6ZR5: crystal structure of jnk1 in complex with atf2(19-58) (10.1038/S41467-020-19582-3 )
• 7CML: the crystal structure of human jnk2 from wuxi biortus.